A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) Meeting Abstract
| Authors: | Younes, A.; Zinzani, P. L.; Sehn, L. H.; Johnson, P. W. M.; Gascoyne, R. D.; Ahmedi, T.; Bellew, K. M.; Vermeulen, J.; Zhuang, S. H.; Sun, S.; Staudt, L. M.; Wilson, W. H. |
| Abstract Title: | A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL) |
| Meeting Title: | 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 32 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2014 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2014-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358613202217 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2014.32.15_suppl.TPS8615 |
| Notes: | Meeting Abstract: TPS8615 -- Source: Wos |
